Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Jesus G M ParionaDepartment of Clinical Analysis, Faculty of Pharmaceutical Sciences, Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0001-9174-0749
Felipe Vásquez-PonceOne Health Brazilian Resistance Project (OneBR), São Paulo, Brazil.ORCID 0000-0002-9447-8325
Johana BecerraOne Health Brazilian Resistance Project (OneBR), São Paulo, Brazil.
Thais Martins-GonçalvesOne Health Brazilian Resistance Project (OneBR), São Paulo, Brazil.
Eva M M ParionaUniversidad Peruana Cayetano Heredia, Unidad de Investigación de Enfermedades Emergentes y Cambio Climático, San Martín de Porres, Peru.
Fabio T MadueñoEscola Politécnica, Engenharia Elétrica, Universidade de São Paulo, São Paulo, Brazil.
Fernanda EspositoDepartment of Clinical Analysis, Faculty of Pharmaceutical Sciences, Universidade de São Paulo, São Paulo, Brazil.
Aline V de LimaDepartment of Clinical Analysis, Faculty of Pharmaceutical Sciences, Universidade de São Paulo, São Paulo, Brazil.
Jorge L Mello SampaioDepartment of Clinical Analysis, Faculty of Pharmaceutical Sciences, Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0001-7789-3028
Rodrigo S GalhardoDepartment of Microbiology, Instituto de Ciências Biomédicas II, Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0002-5686-9704
Nilton LincopanDepartment of Clinical Analysis, Faculty of Pharmaceutical Sciences, Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0003-0161-5800
Funding
Agencia Nacional de Investigación y Desarrollo (ANID) 2020-72210089Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 314336/2021-4, 422984/2021-3Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2019/15578-4Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2020/08224-9Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2023/18292-0
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible · full record | OpenQuestion